Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Follow-Up Questions
Prelude Therapeutics Inc 'in CEO'su kimdir?
Dr. Krishna Vaddi 2016 'den beri şirketle birlikte olan Prelude Therapeutics Inc 'in Chief Executive Officer 'ıdır.
PRLD hissesinin fiyat performansı nasıl?
PRLD 'in mevcut fiyatı $0.9898 'dir, son işlem günde 0.5% increased etti.
Prelude Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Prelude Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 6 analist Prelude Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 5 al, 1 tut, 1 sat ve 3 güçlü sat içermektedir
